BiotechTube

1mg elsunersen + 0.5mg elsunersen

Phase 3Recruiting
1 views this week 0 watching⚡ Active
Interest: 44/100
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Epileptic Encephalopathy

Conditions

Epileptic Encephalopathy, SCN2A Encephalopathy

Trial Timeline

Aug 13, 2025 → Dec 1, 2028

NCT ID
NCT07019922

About 1mg elsunersen + 0.5mg elsunersen

1mg elsunersen + 0.5mg elsunersen is a phase 3 stage product being developed by Praxis Precision Medicines for Epileptic Encephalopathy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07019922. Target conditions include Epileptic Encephalopathy, SCN2A Encephalopathy.

What happened to similar drugs?

0 of 3 similar drugs in Epileptic Encephalopathy were approved

Approved (0) Terminated (0) Active (3)
🔄LorazepamPfizerPhase 3
🔄1.0mg/kg/day PRAX-562 + 1.5mg/kg/day PRAX-562 + PlaceboPraxis Precision MedicinesPhase 3
🔄SAGE-547 + PlaceboSupernus PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
17
Activity
15
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07019922Phase 3Recruiting

Competing Products

14 competing products in Epileptic Encephalopathy

See all competitors
ProductCompanyStageHype Score
Perampanel Oral Suspension + Perampanel TabletEisaiPhase 2
42
LorazepamPfizerPhase 3
40
LorazepamPfizerPre-clinical
26
levetiracetam (add-on)UCBPhase 2
31
ESES treated with clobazamLundbeckPre-clinical
23
NBI-921352 + PlaceboNeurocrine BiosciencesPhase 2
24
NBI-827104Neurocrine BiosciencesPhase 2
24
NBI-921352Neurocrine BiosciencesPhase 2
36
NBI-827104 + PlaceboNeurocrine BiosciencesPhase 2
32
Epidiolex 100 mg/mL Oral SolutionJazz PharmaceuticalsPhase 1
26
1.0mg/kg/day PRAX-562 + 1.5mg/kg/day PRAX-562 + PlaceboPraxis Precision MedicinesPhase 3
44
SAGE-547Supernus PharmaceuticalsPre-clinical
20
SAGE-547Supernus PharmaceuticalsPhase 1/2
26
SAGE-547 + PlaceboSupernus PharmaceuticalsPhase 3
34